RNS Number:8204I
Schering AG
17 March 2003



FDA approves expanded label for Betaferon(R)

Berlin, March 17, 2003 - Schering AG, Germany (FSE: SCH; NYSE: SHR) announced
today that the U.S. Food and Drug Administration (FDA) has approved new labeling
for the multiple sclerosis (MS) treatment Betaferon(R) (interferon beta-1b) for
SC Injection, expanding its indication to treat all relapsing forms of MS to
reduce the frequency of clinical exacerbations. Relapses are repeat attacks
during which new symptoms appear or existing symptoms worsen, followed by
periods of recovery. Relapsing forms of MS include relapsing-remitting MS, the
most common form, and secondary progressive MS with relapses.

"This approval underlines the strength of Betaferon(R), our top selling product.
With the expanded, new label, physicians now can rely on a broader range of
treatment options with Betaferon(R) for the benefit of their patients," said Dr.
Joachim-Friedrich Kapp, Head of the Specialized Therapeutics business area at
Schering AG, Germany. "After another successful year of growth for Betaferon(R)
in 2002, we are confident to reach double-digit growth in 2003 again."

Betaferon(R) (Interferon beta-1b) is marketed in the USA as Betaseron(R) by
Berlex Laboratories, Inc., the US member of the Schering AG Group.

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Diagnostics&
Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for
disabling diseases in the fields of the central nervous system, oncology and
cardiovascular system. As a global player with innovative products Schering AG
aims for leading positions in specialized markets worldwide. With in-house R&D
and supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG,
Berlin, Germany.

Your contacts at Corporate Communication:

Business: Dr Friedrich von Heyl, T: +49-30-468 152 96;
friedrich.vonheyl@schering.de

Investor Relations: Peter Vogt, T: +49-30-468 128 38; peter.vogt@schering.de

Pharma: Dr Claudia Schmitt, T: +49-30-468 158 05, claudia.schmitt@schering.de

Your contacts in the US:

Media Relations: Jeanine O'Kane, T:+1-973-487 2095, jeanine_O'kane@berlex.com

Investor Relations: Joanne Marion, T: +1-973-487 2164, joanne_marion@berlex.com

Find additional information at: www.schering.de/eng



Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives. Undue reliance should not be placed
on such statements because, by their nature, they are subject to known and
unknown risks and uncertainties and can be affected by other factors that could
cause actual results and Schering AG's plans and objectives to differ materially
from those expressed or implied in the forward-looking statements. Certain
factors that may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future events
or circumstances or otherwise.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

REAJRMJTMMIBBFJ